Next Article in Journal
Improved Therapeutic Efficacy of CBD with Good Tolerance in the Treatment of Breast Cancer through Nanoencapsulation and in Combination with 20(S)-Protopanaxadiol (PPD)
Previous Article in Journal
Thermosensitive PLGA–PEG–PLGA Hydrogel as Depot Matrix for Allergen-Specific Immunotherapy
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceutics
Volume 14
Issue 8
10.3390/pharmaceutics14081532
Review Report
pharmaceutics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Review
Peer-Review Record

Non-Invasive Nasal Discharge Fluid and Other Body Fluid Biomarkers in Alzheimer’s Disease

Pharmaceutics 2022, 14(8), 1532; https://doi.org/10.3390/pharmaceutics14081532
by Da Hae Jung 1,2,†, Gowoon Son 1,†,‡, Oh-Hoon Kwon 2,†, Keun-A Chang 3,4,5 and Cheil Moon 1,2,*
Reviewer 1:
Vesa Cosmin Mihai
Reviewer 2:
Dinesh Kumar Verma
Reviewer 3: Anonymous
Pharmaceutics 2022, 14(8), 1532; https://doi.org/10.3390/pharmaceutics14081532
Submission received: 21 June 2022 / Revised: 12 July 2022 / Accepted: 19 July 2022 / Published: 22 July 2022
(This article belongs to the Section Biologics and Biosimilars)

Round 1

Reviewer 1 Report

The work is very interesting. the chapaters are well build an the information is usefull for the non-invasive diagnosis of Alzheimer disease. please discuss if methods such as miRNA can be used from the samples of fluid you discussed. please chceck: https://pubmed.ncbi.nlm.nih.gov/34357520/. Minor revision.

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Reviewer 2 Report

The manuscript (pharmaceutics-1803813) unambiguously describes about peripheral biomarkers, AD diagnosis guidelines, potential of non-invasive bodily fluid biomarkers. Summaries provided in form of the table is another upside of this manuscript. Authors have well described conventional AD body fluid biomarkers and their limitations. Since the main focus of this manuscript is on peripheral body fluid biomarkers which are reviewed only in positive way. While the tables do show the contradiction, for example, table 9 shows Aβ42 inconsistent presence in the saliva of AD patients. As of now there is no reliable peripheral body fluid biomarkers which can be assigned as hallmark for the AD detection. So, there is concern about the limitations to detect the biomarkers in the peripheral body fluids. To improve the manuscript and to balance out between pros and cons, my suggestion is –

 Major Concern-

1.    Authors are suggested to add a section to discuss the limitations with proper references in the detection of the biomarkers from the peripheral body fluids samples.

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Reviewer 3 Report

1) In introduction, introduce the problem, motivate the problem and summarize the main contributions

2) No literature survey

3) Show the main limitations in the exsisting works and how the proposed approach overcomes these limitations

4) Include future works

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Round 2

Reviewer 2 Report

Thank you for adding the limitation section. No more concerns from my side.

Back to TopTop